Granted Patent B2

US 12,583,838 · App. 17/817,853 · Granted Mar 24, 2026

Inventors: Aleksandrs Zavoronkovs (Hong Kong, CN); Aleksandr Aliper (Ramenskoye, RU); Vladimir Aladinskiy (Kaliningrad, RU); Andrey Kukharenko (Moscow, RU)

Assignee: INSILICO MEDICINE HONG KONG LIMITED

C07D403/04A61P11/00A61P13/12C07D233/90C07D401/04C07D403/14C07D405/04C07D487/08

Abstract

Claims (18)

1 . A compound represented by Formula (IIA),

or a pharmaceutically acceptable salt thereof, wherein:

R 1 is selected from

substituted C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is substituted with one or more substituents selected from halogen, —OH, —CN, —NO 2 , —NH 2 , oxo, ═S, —C 1-10 haloalkyl, —O—C 1-10 alkyl, —O—C 1-6 alkyl-O—C(O)(O—C 1-10 alkyl), C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 carbocycle, and 3- to 12-membered heterocycle; and

3 to 8-membered heterocycle, wherein the 3 to 8-membered heterocycle is optionally substituted with one or more substituents selected from halogen, —OH, —CN, —NO 2 , —NH 2 , oxo, ═S, —S(O 2 )NH 2 , —C 1-10 haloalkyl, —O—C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 carbocycle, 3- to 12-membered heterocycle, and optionally substituted C 1-10 alkyl, wherein the C 1-10 alkyl is optionally substituted with one or more substituents selected from hydroxy, halogen, oxo, —C 1-10 haloalkyl, —NH 2 , —CN, and —NO 2 ;

R 3 is phenyl, which is optionally substituted with one or more substituents selected from halogen, —OH, —CN, —NO 2 , —NH 2 , exe, —S, C 1-6 alkyl, and —C 1-10 haloalkyl; and

R 4 is non-halogenated C 1 -C 6 alkyl.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4 is selected from

3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is substituted phenyl, and wherein the phenyl is substituted with one or more substituents selected from halogen and —C 1-10 haloalkyl.

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1 is substituted C 1 -C 6 alkyl, wherein the C 1 -C 6 alkyl is substituted with one or more substituents selected from halogen, —OH, —CN, —NO 2 , —NH 2 , oxo, ═S, —C 1-10 haloalkyl, —O—C 1-10 alkyl, —O—C 1-6 alkyl-O—C(O)(O—C 1-10 alkyl), C 2-10 alkenyl, C 2-10 alkynyl, C 3-12 carbocycle, and 3- to 12-membered heterocycle.

5 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 1 is substituted with one or more substituents selected from oxo, halogen, —O—C 1-10 alkyl, —C 1-10 haloalkyl, and —OH.

6 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 1 is substituted with one or more substituents selected from —OH, oxo, and —O—C 1-10 alkyl.

7 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

8 . The compound of claim 4 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

9 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R1 is an optionally substituted bicyclic heterocycle.

10 . The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 1 is an optionally substituted bridged bicyclic heterocycle.

11 . The compound of claim 9 , or a pharmaceutically acceptable salt thereof, wherein R 1 is

12 . A pharmaceutical composition comprising (i) a compound of claim 1 or a pharmaceutically acceptable salt thereof; and (ii) a pharmaceutically acceptable excipient.

Assignments (4)

Priority Claims (2)

Continuity (2)

References Cited (99)